QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint

QuidelOrtho Corp

2024-FY EPS reported -$30.54 revenue$2,782,900,000

Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.
CEO states 'positive note' and expects top-line above 2024 guidance midpoint; full results due Feb 12, 2025.
Company highlights cost-savings initiatives and leadership realignment during fiscal 2024.
Respiratory revenue ranges reflect lower Q4 demand compared to prior year; Labs segment also in line.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.